Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off

Novartis today completed the spin-off of the Alcon eye care devices business through a dividend-in-kind distribution to holders of Novartis shares and ADRs (American Depositary Receipts), with each holder receiving 1 Alcon share for every 5 Novartis shares or ADRs held on April 8, 2019, at the close of business.

Source: World Pharma News - April 9, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news